Maarten P Van Den Berg

List of Publications by Year
in descending order

82 papers	4,167 citations	136950 32 h-index	123424 61 g-index
86 all docs	86 docs citations	86 times ranked	6084 citing authors

#	Article	IF	Citations
1	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	7.1	369
2	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	2.2	338
3	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	21.4	281
4	Genetics, Clinical Features, and Long-TermÂOutcome of NoncompactionÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 711-722.	2.8	242
5	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	2.2	159
6	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	3.8	148
7	Outcome in Phospholamban R14del Carriers. Circulation: Cardiovascular Genetics, 2014, 7, 455-465.	5.1	146
8	Bone scintigraphy with^{99m}technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 35-44.	3.0	129
9	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 512-521.	7.1	127
10	Genotype impacts survival in Marfan syndrome. European Heart Journal, 2016, 37, 3285-3290.	2.2	114
11	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	2.2	96
12	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
13	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	4.8	82
14	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. Circulation: Heart Failure, 2014, 7, 723-731.	3.9	74
15	Periprocedural Complications andÂLong-Term Outcome AfterÂAlcoholÂSeptalÂAblation VersusÂSurgical MyectomyÂin Hypertrophic Obstructive Cardiomyopathy. JACC: Cardiovascular Interventions, 2014, 7, 1227-1234.	2.9	64
16	The Prognostic Value of RightÂVentricularÂDeformation Imaging inÂEarlyÂArrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 446-455.	5.3	64
17	Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	2.2	63
18	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. Heart Rhythm, 2014, 11, 1543-1550.	0.7	62

#	Article	IF	Citations
19	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
20	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
21	Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. European Heart Journal, 2020, 41, 4181-4187.	2.2	54
22	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriersâ€“reaching the frontiers of individual risk prediction. European Heart Journal, 2021, 42, 2842-2850.	2.2	54
23	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	2.9	50
24	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	1.2	48
25	Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology, 2016, 69, 542-550.	2.9	46
26	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	8.2	42
27	Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart, 2014, 1, e000116.	2.3	40
28	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	2.2	39
29	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	3.3	38
30	Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genetics in Medicine, 2018, 20, 1374-1386.	2.4	36
31	Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly. JACC: Cardiovascular Interventions, 2016, 9, 463-469.	2.9	35
32	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	2.2	35
33	Relevance of Titin Missense and Non-Frameshifting Insertions/Deletions Variants in Dilated Cardiomyopathy. Scientific Reports, 2019, 9, 4093.	3.3	30
34	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace, 2014, 16, 1417-1425.	1.7	29
35	An International Multicenter Cohort Study on Î²-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
36	Familial dilated cardiomyopathy: another risk factor for anthracyclineâ€induced cardiotoxicity?. European Journal of Heart Failure, 2010, 12, 1297-1299.	7.1	27

#	Article	IF	Citations
37	Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). European Journal of Human Genetics, 2014, 22, 293-293.	2.8	27
38	Sudden Cardiac Arrest and Rare Genetic Variants in the Community. Circulation: Cardiovascular Genetics, 2016, 9, 147-153.	5.1	27
39	Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. Intensive Care Medicine, 2006, 32, 281-285.	8.2	24
40	Diurnal variation of ventricular repolarization in a large family with LQT3-Brugada syndrome characterized by nocturnal sudden death. Heart Rhythm, 2006, 3, 290-295.	0.7	22
41	A new fully covered metal stent with anti-migration features for the treatment of malignant dysphagia. Endoscopy, 2014, 46, 1101-1105.	1.8	22
42	Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome. Circulation Research, 2018, 122, 846-854.	4.5	22
43	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. American Journal of Cardiology, 2018, 121, 107-112.	1.6	22
44	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. Journal of Clinical Investigation, 2021, 131, .	8.2	22
45	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. International Journal of Cardiology, 2018, 266, 128-132.	1.7	21
46	Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. International Journal of Cardiology, 2014, 171, 90-92.	1.7	20
47	Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients. Europace, 2019, 21, 1519-1526.	1.7	20
48	Electrocardiographic Features Differentiating Arrhythmogenic RightÂVentricular Cardiomyopathy FromÂan Athleteâ€™s Heart. JACC: Clinical Electrophysiology, 2018, 4, 1613-1625.	3.2	19
49	TAB2 deletions and variants cause a highly recognisable syndrome with mitral valve disease, cardiomyopathy, short stature and hypermobility. European Journal of Human Genetics, 2021, 29, 1669-1676.	2.8	19
50	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovascular Pathology, 2017, 30, 23-26.	1.6	17
51	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. European Heart Journal, 2018, 39, 2898-2907.	2.2	17
52	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	2.3	17
53	The first titin (c.59926 + 1G > A) founder mutation associated with dilated cardiomyopathy. European Journal of Heart Failure, 2018, 20, 803-806.	7.1	16
54	Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovascular Pathology, 2019, 40, 2-6.	1.6	16

#	Article	IF	Citations
55	Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathy. Journal of Medical Genetics, 2020, 57, 23-30.	3.2	16
56	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	1.7	15
57	Brugada Syndrome with ST-Segment Elevation in the Lateral Leads. Journal of Cardiovascular Electrophysiology, 2006, 17, 1035-1035.	1.7	13
58	Early Mechanical Alterations in Phospholamban Mutation Carriers. JACC: Cardiovascular Imaging, 2021, 14, 885-896.	5.3	11
59	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. Circulation Genomic and Precision Medicine, 2018, 11, e001797.	3.6	10
60	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007471.	4.8	10
61	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 306-318.	3.2	10
62	The electrocardiographic manifestations of athlete's heart and their association with exercise exposure. European Journal of Sport Science, 2018, 18, 587-593.	2.7	9
63	The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. International Journal of Molecular Sciences, 2021, 22, 2955.	4.1	9
64	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace, 2022, 24, 296-305.	1.7	9
65	Transthyretin-Derived (ATTR) Amyloidotic Cardiomyopathy After Receiving a Domino Liver Allograft. Circulation, 2015, 132, e216-7.	1.6	8
66	Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison. European Journal of Human Genetics, 2017, 25, 169-175.	2.8	8
67	The effect of tropomyosin variants on cardiomyocyte function and structure that underlie different clinical cardiomyopathy phenotypes. International Journal of Cardiology, 2021, 323, 251-258.	1.7	8
68	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm, 2022, 19, 427-434.	0.7	8
69	Aortic distensibility in Marfan syndrome: a potential predictor of aortic events?. Open Heart, 2021, 8, e001775.	2.3	7
70	Genome-wide methylation patterns in Marfan syndrome. Clinical Epigenetics, 2021, 13, 217.	4.1	7
71	Three female patients with Danon disease presenting with predominant cardiac phenotype: a case series. European Heart Journal - Case Reports, 2019, 3, ytz132.	0.6	6
72	Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers. European Heart Journal Cardiovascular Imaging, 2022, 23, 1492-1501.	1.2	6

#	Article	IF	Citations
73	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2022, 19, 1659-1665.	0.7	6
74	Mortality Risk Associated With Truncating Founder Mutations in Titin. Circulation Genomic and Precision Medicine, 2019, 12, e002436.	3.6	5
75	Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487.	3.8	5
76	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Cardiovascular Pathology, 2017, 29, 19-22.	1.6	3
77	Functional investigation of two simultaneous or separately segregating DSP variants within a single family supports the theory of a doseâ€dependent disease severity. Experimental Dermatology, 2022, , .	2.9	3
78	Rhythmic ECG Changes in a Patient with Long QT Syndrome Type 3. Journal of Cardiovascular Electrophysiology, 2007, 18, 1342-1343.	1.7	2
79	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	2.5	2
80	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	3.0	2
81	Dyssynchronopathy Can be a Manifestation of Heritable Cardiomyopathy. Circulation Genomic and Precision Medicine, 2019, 12, e002528.	3.6	0
82	Coexistence of wild type and hereditary ATTR amyloidosis in one family. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 71-72.	3.0	0